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High Donor and Recipient Age Are Not Risk Factors for
Chronic Graft-Versus-Host Disease in the Setting of Anti-
Thymocyte Globulin-Conditioned Hematopoietic Stem
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Rabbit anti-thymocyte globulin (ATG) given with condi-
tioning for allogeneic haematopoietic stem cell trans-
plantation (alloHSCT) is effective in reducing the risk of
chronic graft-versus-host disease (cGVHD). Whether
conventional risk factors for cGVHD apply to ATG-condi-
tioned alloHSCT is not known. Between the years 2004 and
2011, 356 adults (median age 48) from 3 centres received 4.5
mg/kg of Thymoglobulin prior to alloHSCT for haematologic
malignancy (acute leukaemia 58%, chronic myeloid
leukaemia 6%, othermyeloidmalignancy 15%, other lymphoid
malignancy 21%). Donors were unrelated in 64%. Condi-
tioning was myeloablative in 94%. Peripheral blood grafts
were used in 97%. At 3 years, overall survivalwas61.0% (95%CI
55.3-67.3%), cumulative incidence of relapse was 32.6% (95%
CI 26.2-38.5%) and transplant-related mortality was 18.8%
(13.2-24.1%). 342 patients were evaluable for the primary
endpoint of cGVHD requiring systemic immunosuppression
(cGVHD-IS). The cumulative incidence of cGVHD-IS at 3 years
was 37.2% (95% CI 31.1-42.7%). On multivariate analysis, only
prior grade 2-4 aGVHD (HR 3.08, 95% CI 2.10-4.52, P < .001)
was associated with a signiﬁcant increase in risk of cumula-
tive incidence of cGVHD-IS. Recipient age of greater than 40
years was associated with signiﬁcantly less cGVHD-IS (HR
0.66, 95% CI 0.45-0.97, P ¼ .03) in univariate but not multi-
variate analysis. The use of unrelated donors, donor age over
40, female donor/male recipient gender combination and
recipient CMV seropositivity were not associated with
increased cGVHD-IS. There was insufﬁcient power to deter-
mine the effect of graft type (peripheral blood vs bone
marrow) on cGVHD-IS, but the incidence did not appear
higher in peripheral blood graft recipients. In summary, in
this cohort, traditional pre-transplant risk factors for cGVHD
were not predictive. In patients undergoing in vivo T-cell
depleted alloHSCT, novel predictors of cGVHDmaybeneeded.451
Sub-Therapeutic Levels of Oral Tacrolimus Prophylaxis
Prior to Allogeneic Stem Cell Transplant Do Not Predict
the Incidence of Chronic Graft Versus Host Disease
Jill MacPherson, Carlos Bachier, Ashley Simpson,
Paul J. Shaughnessy. Adult Blood and Marrow Transplant,
Texas Transplant Institute, San Antonio, TXChronic graft versus host disease (cGVHD) is a common
complication of allogeneic stem cell transplantation (ASCT).
Tacrolimus prophylaxis has been proven to be instrumental
in the prevention of acute graft versus host disease (aGVHD)
a common precursor to developing cGVHD. Our institution
uses oral tacrolimus prior to ASCT because we perform ASCT
in the outpatient setting and increases ease of administra-
tion. We retrospectively reviewed our experience in 94
consecutive patients (pts) who received ASCT from 10 /10
HLAmatched donors, 47 werematched sibling donors (MSD)
and 47matched unrelated donors (MUD) with a median age
of 50 and 52 respectively. All patients received GVHD
prophylaxis with tacrolimus started orally between day -3
and day -1 at a dose of 0.06mg/kg per day divided twice daily.
Standard short course methotrexate (MTX) was prescribed
for all pts (D1 dose 15mg/m2, D3, 6, and 11 doses at 10mg/
m2). Pts who had sub-therapeutic tacrolimus levels (less
than 5ug/L) on the day of transplant (D0) were compared to
pts who had therapeutic tacrolimus levels (greater than 5ug/
L) for incidence of cGVHD and overall survival. Sixty-eight pts
had tacrolimus levels less than 5ug/L on D0 and 26 pts had
tacrolimus of 5ug/L or greater. Fifty eight of the 94 patients
developed cGVHD and 36 did not develop cGVHD indicating
that there was no signiﬁcant difference in the incidence of
cGVHD in these patients despite the level of tacrolimus on
D0. The 58 pts that developed cGVHD, 42/68 (62%) had
a tacrolimus level less than 5ug/L.The 36 pts that did not
develop cGVHD, 26/68 (38%) had a tacrolimus level less than
5ug/L. With a median follow up of 463 days 54/94 pts (57%)
survive; 40/68 pts (59%) with D0 tacrolimus levels that were
less than 5ug/L, and 14/26 pts (54%) with D0 tacrolimus
levels were greater than or equal to 5ug/L. In conclusion, oral
tacrolimus prophylaxis prior to ASCT at our institution
results in sub-therapeutic levels on the day of transplant in
the majority of patients, however, this does not appear to
impact the overall incidence of cGVHD or survival. As an
incidental ﬁnding, those who developed cGVHD had longer
overall survival versus those who did not develop cGVHD.
This study was limited by its retrospective nature, small size
and single center experience.452
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Donor T cell alloreactivity in hematopoietic stem cell trans-
plantation (HCT) can result in acute graft-versus-host disease
(GVHD) which is a major cause of morbidity and mortality in
HCT. We hypothesized that using T cell receptor repertoire
sequencing, we could identify the most frequent T cell clones
in the gastrointestinal (GI) tract of human patients with
GVHD and subsequent tracking of these disease-associated
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patients.
We collected endoscopic GI tract biopsy samples and
matched blood for fourteen patients undergoing myelo-
blative HCT with suspected GI GVHD within one day of
corticosteroid therapy. We also collected peripheral blood
approximately thirty days after biopsy. Seven of these
patients were negative for GVHD or had mild steroid
responsive GI GVHD and seven had severe steroid refractory
GI GVHD. We extracted genomic DNA and performed TCR
beta CDR3 repertoire sequencing at Stanford and with
Gigagen GigaMune Rep-Seq, using the Illumina next gener-
ation sequencing MiSeq and HiSeq platforms.
For each patient, between 1,000-5,000 unique T cell
sequences were identiﬁed in the endoscopic tissue. We
bracketed the most frequent clones in the GI tissue samples
by rank order cut-offs and a ﬂoating measure of skewness
and followed these clones in the blood. Both methods
showed that, on average, the GI identiﬁed clones increased in
frequency more in severe patients (51.2 +/- 39.2) when
compared to mild or negative patients (3.08 +/- 2.8; see
Figure 1). Additionally, patients in both groups who received
more steroids (mg/kg/day) showed a correlated reduction in
GI identiﬁed T cell expansion in the blood over time. These
results support the use of T cell repertoire sequencing and
associated approaches in human patients to both clarify the
pathophysiology of GVHD and may provide an independent
immune biomarker that could guide GVHD therapy.
Figure 1. GI identiﬁed TCR sequences become much more frequent in the
blood in an analysis of patients with severe steroid refractory GI GVHD as
compared to a patients with steroid responsive GVHD or without GVHD. (a)
Graphical depiction of the most frequent TCR sequence identiﬁed in the colon
and blood. Top panel shows the increasing frequency of the topped rank clone
(red), in contrast to the lower panel which shows the decreasing frequency of
the top ranked clone (green). (b) The mean fold change of TCR sequences
identiﬁed in the GI tract of patients tracked in the blood at day 30 to day of
diagnosis of 7 patients with severe GVHD and 7 patients with mild or no GVHD
(Wilcoxin Test, P < .002). GI sequences were identiﬁed as the top 100 by rank
order.453
Identiﬁcation of Y-Chromosomally Encoded Minor
Histocompatibility Antigens Using a Reverse Immunology
Approach
Bo Kok Mortensen 1, Peter Brændstrup 1, Malene Erup Larsen 2,
Mette Voldby Larsen 2, Ole Lund 2, Michael Rasmussen 3,
Søren Buus 3, Anette Stryhn 3, Lars Vindeløv 1. 1 Allogeneic
Hematopoietic Cell Transplantation Laboratory, Rigshospitalet,
Copenhagen Ø, Denmark; 2 Center for Biological Sequence
Analysis, DTU Systems Biology, Technical University of
Denmark, Lyngby, Denmark; 3 Laboratory of Experimental
Immunology, University of Copenhagen, Copenhagen N,
Denmark
Introduction: In allogeneic hematopoietic cell trans-
plantation (HCT), minor histocompatibility antigens (mHags)
are known to play an important role in generating immune
responses leading to graft-versus-leukaemia (GVL) effectsand graft-versus-host-disease (GVHD). mHags are results of
polymorphisms in the recipients genome, which cause
expression of peptides that can be recognised by donor T-
cells. Y-chromosomally encoded proteins constitute
a constant source of mHags relevant in allogeneic HCTs with
female donor and male recipient due to the disparities
between these and their homologue X-chromosomally
encoded counterparts.
Methods: A panel containing 8-11 mer peptides encom-
passing multiple putative and knownmHags encoded by the
Y-chromosome was designed using a bioinformatics
predictor of peptide-HLA binding, NetMHCpan. These
peptides were synthesized and used to screen for peptide-
speciﬁc T-cell responses in peripheral blood mononuclear
cells (PBMCs) obtained post-HCT from male recipients of
female donor grafts. Following in vitro stimulation, PBMCs
were analysed with an inteferon-g ELISpot assay. When
a response was found, the T-cells were further analyzed with
intracellular cytokine staining (ICS) and ﬂow cytometry to
determine whether it was a CD4- or a CD8-response. The
optimal epitope and the HLA-restriction was determined by
tetramer staining.
Results: In one male recipient of a female donor graft a T-cell
response was observed with ELISpot against the peptides
YFYYNAFHWAI and RESEEESVSL. ICS and ﬂow cytometry
revealed that both were CD8 responses. Both peptides were
earlier described mHags restricted by HLA-A*24:02 and HLA-
B60, respectively. Tetramer staining conﬁrmed that the
optimal epitopes were YYNAFHWAI and RESEEESVSL pre-
sented on HLA-A*24:02 and HLA-B*40:01 (a member of the
previously designated HLA-B60 speciﬁcity), respectively.
PBMCs obtained post HCT from ﬁve other male recipients of
female donor grafts have been analysed for T-cell responses
with ELISpot. Responses have been observed and further
analysis is ongoing.
Conclusion: Using a HLA-tetramer approach to identify the
optimal epitopes of two known mHags encoded by the Y-
chromosome as well as the presenting HLA restriction
elements at high resolution, we have demonstrated the
feasibility of a reverse immunology approach in mHag dis-
covery.454
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Pulmonary function post allogeneic hematopoietic stem cell
transplant (HSCT) can be impaired by previous exposure to
chemotherapy, infection, or graft versus host disease
(GVHD). In this retrospective study, we analyzed 21 patients
with hematologic malignancies who are long term trans-
plant survivors with a median follow-up of 48 months who
had received a related (60%) or unrelated (40%) HSCT
conditionedwith a busulfan-based regimen. Of 21 patients, 7
are of Caucasian and 14 non-Caucasian ethnicity. All patients
had routine pulmonary function tests (PFTs) repeated within
two years from transplant and none had underlying lung
disease. To eliminate inter-lab variability, all PFTs were
